Chemistry:Zatolmilast
From HandWiki
Zatolmilast is a investigational new drug that is being evaluated to treat fragile X syndrome.[1] It is a PDE4D allosteric inhibitor.[2]
It works by inhibiting breakdown of cyclic AMP (cAMP), with increased cAMP levels thought to increase neuronal connectivity. It has shown increased caregiver symptoms ratings and cognitive scores in a small clinical trial of 30 adults with fragile X syndrome.[3]
References
- ↑ "Zatolmilast - Tetra Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800044083.
- ↑ "Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review". Dermatology and Therapy 13 (12): 3031–3042. December 2023. doi:10.1007/s13555-023-01054-3. PMID 37924462.
- ↑ "The Spectrum of Fragile X Disorders". New England Journal of Medicine 393 (3): 281–288. 17 July 2025. doi:10.1056/NEJMra2300487. PMID 40673587.
 |  |
